Search results: (10000)
News Reducing Overall Mortality by Combining Three Antihypertensives into a Single Pill
Treating hypertension to recommended target blood pressure values often requires a combination of three antihypertensives. By simply combining these three substances into a single pill, it is possible to increase treatment adherence, reduce overall mortality in hypertensive patients, and lower healthcare costs within one year. This is demonstrated by a freshly published Italian real-world study.
News Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent
In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS in adults who have not responded adequately to conventional systemic therapy.
News Subcutaneous vs. Intravenous Immunoglobulins in Patients with CLL
Secondary antibody immunodeficiency is a common complication in patients with chronic lymphocytic leukemia (CLL), and infections, along with secondary malignancies, are the leading cause of death in these patients. Hypogammaglobulinemia can be managed with immunoglobulin replacement therapy (IGRT). Besides the classic intravenous form (IVIG), a subcutaneous form (SCIG) is also available. An Italian retrospective study published in the journal Current Oncology compared their efficacy in secondary immunodeficiency in CLL patients.
News The Role of Inflammation in the Cardiovascular Continuum and the Aging Process
Inflammation plays a role at various stages of the cardiovascular (CV) continuum, in both atherosclerotic and non-atherosclerotic CV diseases. Where to look for inflammation in the pathophysiology of CV diseases, why inflammation is related to aging, and how to utilize these findings in clinical practice was explained in a lecture by MUDr. Peter Wohlfahrt, Ph.D., from the Center of Preventive Cardiology IKEM in Prague, at the XXXII Annual Meeting of the Czech Cardiology Society.
News With MD Eva Drbohlavová on Innovations in the Treatment of von Willebrand Disease and Improving Patients' Quality of Life
Von Willebrand Disease (vWD), as the most common congenital bleeding disorder, remains underdiagnosed. However, thanks to new insights and advances in genetic testing, both diagnosis and long-term prophylaxis of the disease are gradually improving, leading to a significant reduction in bleeding and better quality of life for patients. We discuss this in more detail with MD Eva Drbohlavová from the Department of Clinical Hematology at the Regional Hospital Liberec.
News Combination of Arterial Hypertension and Increased Heart Rate as a Significant Cardiovascular Risk Factor
Heart rate is one of the basic vital signs that should be regularly measured. Sinus tachycardia can be physiological under certain conditions. However, a patient with resting tachycardia should always be examined, as tachycardia can be a symptom of a serious health problem. Especially in patients with arterial hypertension, a rapid heart rate significantly increases cardiovascular risk.
News Fibrinogen and Management of Peripartum Life-Threatening Hemorrhage
The most common cause of maternal death in the developed world continues to be peripartum life-threatening hemorrhage. It can result as a consequence of the consumption of coagulation factors, primarily fibrinogen. The analysis presented below summarizes information on the prevention of this complication and the use of fibrinogen concentrate therapy.
News Maintenance Therapy After Oxaliplatin Discontinuation Based on Panitumumab
Panitumumab is an approved therapy for metastatic colorectal cancer without RAS oncogene mutation (wtRAS mCRC) and has been evaluated for 1st-line treatment through randomized phase II (PEAK) and III (PRIME) studies. A retrospective analysis of these studies assessed the efficacy and safety of panitumumab as the basis for therapy in these patients after discontinuation/termination of oxaliplatin.
News Enoxaparin in the Treatment of Pulmonary Embolism in a Morbidly Obese Patient – Case Report
The number of patients suffering from overweight and obesity has been steadily increasing in recent years. Obesity is one of the independent risk factors for thromboembolic disease. Treating thrombotic complications in obese patients poses a challenge not only because of the adjustments in anticoagulant dosing but also due to the lack of evidence regarding the safety and efficacy of higher doses of anticoagulants in this growing group of the population.
News MUDr. Tomáš Mašek: In the prevention of hemorrhoids, more use of venopharmaceuticals is needed
While in the past the diagnosis of hemorrhoids was inextricably linked to traditional surgical solutions, today - thanks to the expansion of the indication for venopharmaceuticals for this condition - the number of patients who have to undergo these procedures is a minority. We asked coloproctologist MUDr. Tomáš Mašek how the potential of venopharmaceuticals can be utilized in the prevention and treatment of hemorrhoid disease.
News What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
A Spanish clinical study monitored the effect of administering probiotics as an adjunct therapy to non-surgical mechanical treatment of peri-implantitis. What did the study show regarding the effect on microbiome composition and overall clinical picture when a preparation containing Limosilactobacillus reuteri Prodentis was administered?
News Metformin − A Proven Helper That Effectively Protects the Heart of Diabetics
Metformin is one of the first-line medications for patients with type 2 diabetes. In addition to lowering blood glucose levels, it also affects other metabolic processes in the human body. Its antitumor, neuroprotective, and especially cardioprotective effects have been extensively studied, which can be advantageously utilized in the diabetic population.
News Genetic Testing in Clinical Practice – An Irreplaceable Tool in Prevention, Diagnosis and Treatment
Genetic testing has long ceased to be the privilege of clinical research. In practice, it is commonly used for screening, diagnosis, and prognosis determination in diseases with an evident genetic component, and subsequently for tailoring pharmacotherapy to the individual patient. The richest experience with genetic testing belongs to reproductive medicine and the field of prenatal diagnostics, as well as pediatrics associated with rare disease medicine and oncology. Today, the significance of testing is becoming apparent in internal medicine and psychiatry as well.
News Bilastine and its role in the treatment of allergic rhinoconjunctivitis and urticaria in children
The prevalence of allergic rhinitis (AR) in the pediatric population is estimated worldwide at 10-20%. The efficacy and safety of bilastine (a second-generation antihistamine) in adult patients and adolescents have already been proven in clinical studies. Below we summarize experiences with its use in children under 12 years of age.
News Venetoclax Treatment Strategies in Patients with CLL
One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is the Bcl-2 inhibitor venetoclax. Its significant advantage is the potential to achieve deep remission, including undetectable minimal residual disease (MRD). Unlike other targeted drugs, it can be administered for a limited period of time. The following text presents current data from clinical trials and information on the strategy of selecting and sequencing targeted CLL treatment.